基于静脉注射用人免疫球蛋白药物三联法治疗小儿重症肺炎的病情程度、体液免疫应激改善研究

Improvement Study of Severity and Humoral Immune Stress of Severe Pneumonia Children Based on Triple Therapy of Intravenous Immunoglobulin Drugs

目的以小儿重症肺炎患者为研究对象,应用静脉注射用人免疫球蛋白药物三联法,以临床疗效、不良反应和小儿患者肺功能、体液免疫指标和应激反应为评价指标,构建研究活动。方法选取广东省高州市人民医院2019年1月-2020年1月收治的66份小儿重症肺炎患者资料,基于治疗方式不同,均分为对照组和研究组,各33例。对照组行常规用药方案,研究组加用人免疫球蛋白药物,观察两组患儿的肺功能指标,体液免疫指标、应激反应指标。结果研究组各项肺功能指标更理想、各项体液免疫指标更高、应激反应指标中除丙二醛水平低于对照组外,其他两项皆优于对照组,P<0.05。结论在针对小儿重症肺炎患者常规治疗的基础上,加用人免疫球蛋白药物,疗效确切,可抑制患儿病情,优化肺功能和体液免疫功能,减少氧化应激损伤,值得推广。

Objective To construct research activity of children with severe pneumonia,with triple method of intravenous immunoglobulin drugs,based on evaluation indicators of clinical effect,adverse reactions,pulmonary function,humoral immunity and stress response of children.Methods The paper chose data of 66 children with severe pneumonia treated in Gaozhou people's Hospital from January 2019 to January 2020,and divided them into control group and study group based on different treatment methods,with 33 cases in each group.Control group was treated with routine medication and study group with human immunoglobulin.Pulmonary function,humoral immunity and stress response of two groups was observed.Results Indexes of lung function and humoral immunity in study group were better than control group,and level of malondialdehyde was lower than control group,the other two indexes were better than control group(P<0.05).Conclusion Human immunoglobulin drugs can achieve definite effect on the basis of routine treatment for severe pneumonia children,can inhibit condition,optimize lung function and humoral immune function,and reduce oxidative stress injury,which is worthy of promotion.